Ferritin level at diagnosis is not correlated with poorer survival in non RBC transfusion dependent lower risk de novo MDS

Leukemia Research

Volumn 35, Issue 11, 2011, Pages 1530-1533

  Park, S ^a   Sapena, R ^a   Kelaidi, C ^b   Vassilieff, D ^a   Bordessoule, D ^c   Stamatoullas, A ^d   Cheze, S ^e   Beyne Rauzy, O ^f   Vey, N ^g   Rose, C ^h   Guerci, A ⁱ   Natarajan Amé, Shanti ^j   Tertian, Gérard ^k   Slama, B ^l   Fenaux, P ^b   Dreyfus, F ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b AVICENNE HOSPITAL   (France)

^c DUPUYTREN UNIVERSITY HOSPITAL   (France)

^d CENTRE HENRI BECQUEREL   (France)

^e CHU Clemenceau   (France)

^f CHU PURPAN   (France)

^g IPC Marseille   (France)

^h HÔPITAL SAINT VINCENT DE PAUL   (France)

ⁱ CHU NANCY BRABOIS   (France)

^j HÔPITAL DE HAUTEPIERRE   (France)

^k BICÊTRE HOSPITAL   (France)

^l CHU d'Avignon   (France)

more..

Author keywords

Anaemia; Iron overload; Myelodysplastic syndrome

Indexed keywords

FERRITIN;

5Q- SYNDROME; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANEMIA; ARTICLE; CONTROLLED STUDY; ERYTHROCYTE TRANSFUSION; FEMALE; FERRITIN BLOOD LEVEL; FRANCE; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; BLOOD TRANSFUSION; FEMALE; FERRITINS; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; RISK FACTORS; SURVIVAL RATE;

EID: 80053957480     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.07.007     Document Type: Article

References (9)

1. Malcovati L., Porta M.G., Pascutto C., Invernizzi R., Boni M., Travaglino E., et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005 Oct 20, 23(30):7594-7603.
2. Cortelezzi A., Cattaneo C., Cristiani S., Duca L., Sarina B., Deliliers G.L., et al. Non-transferrin-bound iron in myelodysplastic syndromes: a marker of ineffective erythropoiesis?. Hematol J 2000, 1(3):153-158.
3. Tehranchi R., Invernizzi R., Grandien A., Zhivotovsky B., Fadeel B., Forsblom A.M., et al. Aberrant mitochondrial iron distribution and maturation arrest characterize early erythroid precursors in low-risk myelodysplastic syndromes. Blood 2005, 106(July (1)):247-253.
4. Nikpour M., Pellagatti A., Liu A., Karimi M., Malcovati L., Gogvadze V., et al. Gene expression profiling of erythroblasts from refractory anaemia with ring sideroblasts (RARS) and effects of G-CSF. Br J Haematol. 2010, 149(June (6)):844-854.
5. Boultwood J., Pellagatti A., Nikpour M., Pushkaran B., Fidler C., Cattan H., et al. The role of the iron transporter ABCB7 in refractory anemia with ring sideroblasts. PloS One 2008, 3(4):e1970.
6. Ljung T., Back R., Hellstrom-Lindberg E. Hypochromic red blood cells in low-risk myelodysplastic syndromes: effects of treatment with hemopoietic growth factors. Haematologica 2004, 89(December (12)):1446-1453.
7. Malcovati L. Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes. Leuk Res 2007, 3(December (31)):S2-S6.
8. Chee C.E., Steensma D.P., Wu W., Hanson C.A., Tefferi A. Neither serum ferritin nor the number of red blood cell transfusions affect overall survival in refractory anemia with ringed sideroblasts. Am J Hematol 2008, 83(August (8)):611-613.
9. de Wart L., de Witte T., Symeonidis A., Hellstro-Lindberg E., Sanz G., Malcovati L., et al. Management of 1000 patients with low and intermediate-1 risk myelodysplastic syndromes in the European Leukemianet MDS registry. Leuk Res 2011, 35:S3. [abst 7].